{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:10:18Z","timestamp":1792444218557,"version":"4.5.0"},"reference-count":22,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Bronchiectasis is a chronic inflammatory airway disease. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), reduces pulmonary inflammation by preventing the activation of neutrophil serine proteases. In the phase II WILLOW trial, brensocatib prolonged time to first exacerbation in patients with bronchiectasis. In this<jats:italic>post hoc<\/jats:italic>analysis we compare clinical outcomes in patients from WILLOW according to baseline disease characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with bronchiectasis treated with brensocatib (10 or 25\u2005mg) or placebo once daily were analysed by baseline Bronchiectasis Severity Index (BSI) score (\u22644 (mild), 5\u20138 (moderate), or \u22659 (severe)), exacerbation history (2 or \u22653 in the previous year), blood eosinophil count (&lt;300\u2005cells per \u00b5L or \u2265300\u2005cells per \u00b5L), long-term macrolide use (\u22656\u2005months; no or yes) and<jats:italic>Pseudomonas aeruginosa<\/jats:italic>culture at screening (negative or positive). End-points were time to first exacerbation, annualised exacerbation rate, change in lung function from baseline, and safety. All patients who received brensocatib were pooled and compared with placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with brensocatib<jats:italic>versus<\/jats:italic>placebo was associated with a longer time to first exacerbation (hazard ratio (95% confidence interval), BSI: \u22644, 0.28 (0.08\u20130.96); 5\u20138, 0.75 (0.35\u20131.60); \u22659, 0.61 (0.35\u20131.04); prior exacerbations: 2, 0.56 (0.34\u20130.90); \u22653, 0.71 (0.32\u20131.59); blood eosinophils per \u00b5L: &lt;300, 0.66 (0.42\u20131.06); \u2265300, 0.49 (0.20\u20131.20); long-term macrolide use: no, 0.60 (0.38\u20130.94); yes, 0.60 (0.25\u20131.45);<jats:italic>P. aeruginosa<\/jats:italic>culture: negative, 0.54 (0.32\u20130.92); positive, 0.68 (0.37\u20131.27)). Safety results were similar across subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Patients treated with brensocatib had a numerically longer time to first exacerbation and reduced annualised rate of exacerbation<jats:italic>versus<\/jats:italic>placebo across all key baseline disease characteristics.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00505-2024","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:58:57Z","timestamp":1724345937000},"page":"00505-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Brensocatib in patients with bronchiectasis: subgroup analyses from the WILLOW trial"],"prefix":"10.1183","volume":"11","author":[{"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Loebinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Teper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fucile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lauterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roald","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian H.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Metersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2025030304052991000_11.1.00505-2024.1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations","volume":"10","author":"Aliberti","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025030304052991000_11.1.00505-2024.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31767-7"},{"key":"2025030304052991000_11.1.00505-2024.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2202OC"},{"key":"2025030304052991000_11.1.00505-2024.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC"},{"key":"2025030304052991000_11.1.00505-2024.5","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00021-2023"},{"key":"2025030304052991000_11.1.00505-2024.6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30053-5"},{"key":"2025030304052991000_11.1.00505-2024.7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0041-1730891","article-title":"Pathophysiology of bronchiectasis","volume":"42","author":"Keir","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"key":"2025030304052991000_11.1.00505-2024.8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/biomedicines9070772","article-title":"T2-high endotype and response to biological treatments in patients with bronchiectasis","volume":"9","author":"Oriano","year":"2021","journal-title":"Biomedicines"},{"key":"2025030304052991000_11.1.00505-2024.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1889OC"},{"key":"2025030304052991000_11.1.00505-2024.10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0015-2023"},{"key":"2025030304052991000_11.1.00505-2024.11","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1164\/rccm.202303-0499OC","article-title":"Inflammatory molecular endotypes in bronchiectasis: a European Multicenter Cohort Study","volume":"208","author":"Choi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025030304052991000_11.1.00505-2024.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021713"},{"key":"2025030304052991000_11.1.00505-2024.13","doi-asserted-by":"crossref","first-page":"102095","DOI":"10.1016\/j.pupt.2021.102095","article-title":"The immunomodulatory effects of macrolide antibiotics in respiratory disease","volume":"71","author":"Pollock","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"2025030304052991000_11.1.00505-2024.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2025030304052991000_11.1.00505-2024.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017"},{"key":"2025030304052991000_11.1.00505-2024.16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00093-0"},{"key":"2025030304052991000_11.1.00505-2024.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202819"},{"key":"2025030304052991000_11.1.00505-2024.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02053-2017"},{"key":"2025030304052991000_11.1.00505-2024.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02052-2017"},{"key":"2025030304052991000_11.1.00505-2024.20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025030304052991000_11.1.00505-2024.21","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203207"},{"key":"2025030304052991000_11.1.00505-2024.22","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01147-w"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00505-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:07:48Z","timestamp":1741003668000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00505-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1183\/23120541.00505-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00505-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}